By Giulia Petroni 
 

Novartis AG (NOVN.EB) said Monday that its subsidiary Medusa Merger Corp. has successfully completed the tender offer for all outstanding shares of Medicines Co. (MDCO) for a price of $85 a share.

The Swiss drug giant said that the offer ended on Jan.3 and approximately 75% of the outstanding shares of the Medicines Co.'s common stock were validly tendered and not withdrawn, with roughly an additional 16.9% being offered.

As a result of the merger, The Medicines Company's stock will cease to be traded on the Nasdaq, according to Novartis.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

January 06, 2020 01:41 ET (06:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novartis Charts.